top of page

Portfolio: Overview

DELIVERING VALUE FOR PATIENTS AND INVESTORS
Harnessing our unique investment approach focused on the translational stage of drug development, combined with our agile operating model for company formation and trial execution, Aditum Bio has launched seven companies to date.
Portfolio
FUND I SNAPSHOT

Launched in 2019, Fund 1 is fully invested in the formation of six portfolio companies.

FUND II SNAPSHOT

Launched in 2021, Fund II is currently deploying capital to form new, innovative companies to meet the needs of patients

OUR PORTFOLIO COMPANIES
Aditum-Portfolio-Company-Versanis.png

Versanis was sold to Eli Lilly for
$1.9 billion in cash and milestone
payments in August 2023

vianova_logo_white.png
Vitalli Bio.png
Trames Bio Logo_edited.png
bottom of page